fleroxacin has been researched along with Urinary Tract Infections in 27 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with symptomatic, complicated urinary tract infection." | 9.08 | Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ( Alpert, NM; Babich, JW; Bonab, A; Chodosh, S; Cleeland, R; Correia, JA; Fischman, AJ; Kamitsuka, P; Liu, YY; Livni, E; McGovern, F; Prosser, BL; Rubin, RH, 1996) |
| "We compared the efficacy and safety of once-daily fleroxacin and twice-daily ciprofloxacin in patients with complicated urinary tract infections." | 9.08 | Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. ( Bischoff, W; Frankenschmidt, A; Kullmann, K; Naber, KG, 1997) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 9.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "Fleroxacin, 400 mg, was compared with amoxicillin, 3,000 mg, each administered orally in a single dose, for the treatment of women with acute uncomplicated symptomatic urinary tract infections." | 9.07 | Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women. ( Brown, P; Rana, C; Silagy, C; Whitby, M, 1993) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 9.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections." | 9.06 | Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. ( Hoepelman, AI; Verhoef, J; Wolfhagen, MJ, 1990) |
| "Fleroxacin also was tested in an uncontrolled trial." | 6.67 | Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. ( Cox, CE, 1993) |
| "Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h." | 5.27 | In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988) |
| "To evaluate the prevention of urinary tract infections (UTIs) after transurethral resection of the prostate (TURP) in a prospective randomized study using a quinolone antibiotic (fleroxacin) to compare the efficacy of: (1) a single oral dose, (2) a single intravenous (IV) dose, and (3) an extended regimen consisting of an initial IV dose followed by oral therapy until removal of the urinary catheter, but for less than 6 days." | 5.08 | Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. ( Christiansen, KJ; England, P; Hall, JC; Hall, JL; Low, AI; Mander, J; McRae, PJ; Taylor, TA, 1996) |
| "The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with symptomatic, complicated urinary tract infection." | 5.08 | Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ( Alpert, NM; Babich, JW; Bonab, A; Chodosh, S; Cleeland, R; Correia, JA; Fischman, AJ; Kamitsuka, P; Liu, YY; Livni, E; McGovern, F; Prosser, BL; Rubin, RH, 1996) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 5.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 5.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections." | 5.06 | Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. ( Hoepelman, AI; Verhoef, J; Wolfhagen, MJ, 1990) |
| "This study enrolled patients with complicated urinary tract infections (UTIs) in a trial to determine the efficacy and safety of sequential therapy with intravenous fleroxacin (first 3 days) followed by oral fleroxacin, for a total course of 7-14 days, both administered at a dosage of 400 mg once a day." | 3.68 | A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection. ( Amarshi, N; Craft, RB; Gelfand, MS; Grogan, J; Simmons, BP, 1993) |
| " Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days." | 2.68 | [A clinical study in the treatment of acute bacterial infections with fleroxacin]. ( Cui, H; Hou, J; Li, J, 1996) |
| "Fleroxacin is a new oral and intravenous trifluorinated 4-quinolone, which acts by inhibiting the essential bacterial enzyme DNA gyrase." | 2.39 | Fleroxacin overview. ( Naber, KG, 1996) |
| " A rabbit model of CAUTI using a closed urinary catheter drainage system and the mutant strain of Escherichia coli (WE 6933) were used to examine three dosage regimens (30 mg/kg q8h i." | 1.29 | Therapeutic efficacy of fleroxacin for eliminating catheter-associated urinary tract infection in a rabbit model. ( Cleeland, R; Costerton, JW; Lam, K; McKay, SG; Morck, DW; Olson, ME; Prosser, B, 1993) |
| "Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h." | 1.27 | In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988) |
| "Fleroxacin is a potent quinolone with in-vitro activity against a variety of resistant bacterial species." | 1.27 | In-vitro activity of fleroxacin against urinary tract and genital tract pathogens. ( Dubois, J; Fontaine, V, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (18.52) | 18.7374 |
| 1990's | 22 (81.48) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosmidis, J | 2 |
| Gargalianos, P | 2 |
| Lelekis, M | 1 |
| Adamis, G | 2 |
| Petropoulou, D | 2 |
| Makris, D | 2 |
| Jones, RN | 1 |
| Erwin, ME | 1 |
| Hager, HL | 1 |
| Hohl, PE | 1 |
| Pummer, K | 1 |
| Pittman, W | 1 |
| Moon, JO | 1 |
| Hamrick, LC | 1 |
| Cox, CE | 2 |
| Clark, J | 1 |
| Childs, S | 1 |
| Pizzuti, D | 1 |
| Fredericks, J | 1 |
| St Clair, P | 1 |
| Childs, SJ | 1 |
| Naber, KG | 5 |
| Sigl, G | 1 |
| Gelfand, MS | 1 |
| Simmons, BP | 1 |
| Craft, RB | 1 |
| Grogan, J | 1 |
| Amarshi, N | 1 |
| Morck, DW | 1 |
| Olson, ME | 1 |
| McKay, SG | 1 |
| Lam, K | 1 |
| Prosser, B | 1 |
| Cleeland, R | 2 |
| Costerton, JW | 1 |
| Iravani, A | 1 |
| Whitby, M | 1 |
| Brown, P | 1 |
| Silagy, C | 1 |
| Rana, C | 1 |
| Gasser, TC | 1 |
| Wisard, M | 1 |
| Frei, R | 1 |
| Hall, JC | 1 |
| Christiansen, KJ | 1 |
| England, P | 1 |
| Low, AI | 1 |
| McRae, PJ | 1 |
| Mander, J | 1 |
| Taylor, TA | 1 |
| Hall, JL | 1 |
| Fischman, AJ | 1 |
| Livni, E | 1 |
| Babich, JW | 1 |
| Alpert, NM | 1 |
| Bonab, A | 1 |
| Chodosh, S | 1 |
| McGovern, F | 1 |
| Kamitsuka, P | 1 |
| Liu, YY | 1 |
| Prosser, BL | 1 |
| Correia, JA | 1 |
| Rubin, RH | 1 |
| Bailey, RR | 1 |
| Giamarellou, H | 1 |
| Frankenschmidt, A | 1 |
| Bischoff, W | 1 |
| Kullmann, K | 1 |
| Hou, J | 1 |
| Li, J | 1 |
| Cui, H | 1 |
| Theuretzbacher, U | 1 |
| Kinzig, M | 1 |
| Savov, O | 1 |
| Sörgel, F | 2 |
| Tsugawa, M | 1 |
| Monden, K | 1 |
| Nasu, Y | 1 |
| Kumon, H | 1 |
| Ohmori, H | 1 |
| Arakawa, S | 1 |
| Takagi, S | 1 |
| Matsumoto, O | 1 |
| Kamidono, S | 1 |
| Sengoku, A | 1 |
| Hazama, M | 1 |
| Yamazaki, H | 1 |
| Hamami, G | 1 |
| Okamoto, Y | 1 |
| Tanaka, H | 1 |
| Wolfhagen, MJ | 1 |
| Hoepelman, AI | 1 |
| Verhoef, J | 1 |
| Kees, F | 1 |
| Schumacher, H | 1 |
| Metz, R | 1 |
| Grobecker, H | 1 |
| Hirai, K | 1 |
| Aoyama, H | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Dubois, J | 1 |
| Fontaine, V | 1 |
3 reviews available for fleroxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Oral fleroxacin prophylaxis in transurethral surgery.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Female; Fleroxacin; Humans; Male; Middle Aged; Po | 1996 |
Fleroxacin overview.
Topics: Animals; Anti-Infective Agents; Drug Interactions; Female; Fleroxacin; Humans; Respiratory Tract Inf | 1996 |
Fleroxacin in complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; Fleroxacin; Humans; | 1996 |
17 trials available for fleroxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fleroxacin; Humans; Male; M | 1993 |
Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fleroxacin; Humans; Male; Middle Aged; | 1993 |
Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Flero | 1993 |
Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Ceftazidime; Female; Fleroxacin; Humans; Infusions, Intrav | 1993 |
Fleroxacin versus ofloxacin in patients with complicated urinary tract infection: a controlled clinical study.
Topics: Adult; Aged; Aged, 80 and over; Female; Fleroxacin; Humans; Male; Middle Aged; Ofloxacin; Prospectiv | 1993 |
Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Ciprofloxacin; Double-Blind Met | 1993 |
Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women.
Topics: Adolescent; Adult; Amoxicillin; Female; Fleroxacin; Humans; Treatment Outcome; Urinary Tract Infecti | 1993 |
Oral fleroxacin prophylaxis in transurethral surgery.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Female; Fleroxacin; Humans; Male; Middle Aged; Po | 1996 |
Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Clinic | 1996 |
Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Fleroxacin; Fluorine | 1996 |
Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Female; Fleroxacin; Humans | 1997 |
[A clinical study in the treatment of acute bacterial infections with fleroxacin].
Topics: Adult; Anti-Infective Agents; Female; Fleroxacin; Fluoroquinolones; Humans; Male; Middle Aged; Quino | 1996 |
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Cross-Over Studies; Enterobacteriaceae; Escheric | 1998 |
Prospective randomized comparative study of antibiotic prophylaxis in urethrocystoscopy and urethrocystography.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cystoscopy; Female; Fleroxacin; Fluoroqu | 1998 |
[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, | 1991 |
Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Dr | 1990 |
Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Ciproflo | 1988 |
8 other studies available for fleroxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Acute, uncomplicated, lower urinary tract infections: the role of single-dose fleroxacin.
Topics: Adolescent; Adult; Age Factors; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topi | 1989 |
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.
Topics: Bacteria; Bronchitis; Clinical Trials as Topic; Europe; False Positive Reactions; Fleroxacin; Humans | 1993 |
A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fleroxac | 1993 |
Therapeutic efficacy of fleroxacin for eliminating catheter-associated urinary tract infection in a rabbit model.
Topics: Animals; Catheters, Indwelling; Disease Models, Animal; Escherichia coli Infections; Fleroxacin; Mal | 1993 |
Single oral dose treatment of uncomplicated urinary tract infection in women.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Cystitis; Female; Fleroxacin; Humans; Urinary Tr | 1996 |
In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Body Fluids; Ciprofloxacin; Fleroxacin; Gram- | 1988 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
In-vitro activity of fleroxacin against urinary tract and genital tract pathogens.
Topics: Ampicillin; Anti-Infective Agents; Bacteria; Ciprofloxacin; Female; Fleroxacin; Genital Diseases, Fe | 1988 |